SOBRE ESTE EPISÓDIO
A single genetic variant can make the difference between effective cancer treatment and life-threatening toxicity. In this episode of LabMind, Ryan Nelson, PharmD, medical director of Precision Medicine at ARUP Laboratories and adjunct professor at the Spencer Fox Eccles School of Medicine at the University of Utah, shares how a growing movement led by patient advocates, researchers, healthcare organizations, and regulators has driven critical updates to guidelines for prescribing fluoropyrimidines, a major class of chemotherapy drugs. Tune in to learn why pharmacogenetic testing is becoming an important tool in cancer care, helping clinicians identify at-risk patients, reduce serious adverse events, and deliver safer, more cost-effective treatments.
Related Information:
- FDA: Safety Labeling Update: Capecitabine and Fluorouracil (5-FU), Risks Associated With DPD Deficiency. 2026. fda.gov
- FDA: VISTOGARD (uridine triacetate) Prescribing Information. 2015.
- NCCN: Clinical Practice Guidelines in Oncology: Colon Cancer, v5.2025 (Oct 30, 2025).
- Nelson R, Shaaban S. DPYD Pretreatment Testing Updates: Guide for Oncologists. ARUP Laboratories, 2026.
- Deenen MJ, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy. J Clin Oncol. 2016;34(3):227-234. doi:10.1200/JCO.2015.63.1325
- Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy. Lancet Oncol. 2018;19(11):1459-1467. doi:10.1016/S1470-2045(18)30686-7
- Knikman JE, et al. Survival With DPYD Variant Alleles and Dose-Individualized. Therapy. J Clin Oncol. 2023;41(35):5411-5421. doi:10.1200/JCO.22.02780
